Journals / Türk Geriatri Dergisi / 2021 / Cilt: 24 - Sayı: 3

RELATIONSHIPS BETWEEN PARKINSON’S DISEASE DEMENTIA AND 25-HYDROXY VITAMIN D AND BRAIN-DERIVED NEUROTROPHIC FACTOR LEVELS

Pages
407–415
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Vitamin D replacement can be used in dementia support treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Parkinson’s disease dementia is an important condition that worsens the quality of life in approximately 30% of parkinson disease patients.
📊
Key Findings & Data:The aim of this study was to investigate the relationship between cognitive impairment and 25-hydroxy vitamin D and brain-derived neurotrophic factor levels in parkinson’s disease dementia patients.
💡
Conclusion & Impact:Vitamin D replacement can be used in dementia support treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Parkinson’s disease dementia is an important condition that worsens the quality of life in approximately 30% of parkinson disease patients. Vitamin D deficiency and brain-derived neurotrophic factor have been implicated in the pathogenesis of alzheimer type dementia, parkinson’s disease, and many neurodegenerative diseases. The aim of this study was to investigate the relationship between cognitive impairment and 25-hydroxy vitamin D and brain-derived neurotrophic factor levels in parkinson’s disease dementia patients. Materials and Method: 25-hydroxy vitamin D and brain-derived neurotrophic factor serum levels were evaluated in patients with parkinson’s disease dementia (n = 63) and healthy controls (n = 33). Brain-derived neurotrophic factor and vitamin D levels were examined using one sample t-tests, and multiple comparisons among independent groups were done using ANOVA post hoc Tukey’s test analysis. Wechsler Memory Scale and MiniMental State Examination were used to evaluate the cognitive functions of the groups. The disease levels of the patients were determined using the Hoehn and Yahr scale and the Unified Parkinson’s Disease Rating Scale. Results: There was a significant negative correlation between the worsening of dementia and vitamin D levels (p = 0.009). However, there were significant negative correlations between the unified parkinson’s disease rating scale daily living activity and Hoehn and Yahr scales and vitamin D levels. No significant relationship was found between brain-derived neurotrophic factor and parkinson’s disease dementia (p = 0.983). Conclusions: Vitamin D deficiency plays a role in cognitive loss in parkinson’s disease dementia. Vitamin D replacement can be used in dementia support treatment.

🔖

Cite This Article

ALTINAYAR, S., DEMİRTAŞ, Y., ERDEMLİ, Z., EKMEKYAPAR, T., TÜRKÖZ, Y. (2022). RELATIONSHIPS BETWEEN PARKINSON’S DISEASE DEMENTIA AND 25-HYDROXY VITAMIN D AND BRAIN-DERIVED NEUROTROPHIC FACTOR LEVELS. Türk Geriatri Dergisi, Cilt: 24 - Sayı: 3, 407–415. https://ajindex.com/articles/623555

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Massano J, Bhatia KP. Clinical Approach to Parkinson’s Disease: Features, Diagnosis, and Principles of Management. Cold Spring Harb Perspect Med.2012; 2 (6): a008870. (PMID: 22675666)
  2. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157 (11): 1015-22(PMID: 12777365)
  3. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia inParkinson’s disease. Mov Disord 2005; 20 (10): 1255-63. (PMID: 16041803)
  4. Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol 2010; 257 (7): 1073-82. (PMID: 20140443)
  5. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 2007; 130 (7): 1787-98. (PMID: 17535834)
  6. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parking’s patients in the UK. The Cam-PaIGN study. Brain. 2004; 127 (3): 550-60. (PMID: 14691062)
  7. Meireles J, Massano J. Cognitive Impairment and Dementia in Parkinson’s Disease: Clinical Features, Diagnosis, and Management. Frontiers in Neurology 2012; 3 (88): 1-15. (PMID: 22654785)
  8. Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog Biophys Mol Biol 2006; 92 (1): 65-79. (PMID: 16546242)
  9. Eyles DW, Burne THJ, John J McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 2013; 34 (1): 47-64. (PMID: 22796576
  10. Wetmore C, Cao Y, Pettersson RF, et al. Brain-derived neurotrophic factor: subcellular compartmentalization and interneuronal transfer as visualised with anti-peptide antibodies. Proc. Nall. Acad. Sci 1991; 88 (21): 9843-47. (PMID: 1946410)
  11. Phillips HS, Hains JM, Armanini M, et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron 1991; 7 (5): 695- 702. (PMID: 1742020)
  12. Holsinger RM, Schnarr J, Henry P, et al. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Brain Res Mol Brain Res 2000; 76 (2): 347-54. (PMID: 10762711)
  13. Howells DW, Porritt M, Wong JY, et al. Reduced BDNF mRNA expression in the Parkinson’s disease